Protagonist Therapeutics price to sales ratio PTGX

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 31.8×
8-year median: 15.4×
Against its 8-year history: 74th; percentile: 0 is its lowest day, 100 its highest
8-year range: 5.2× to 147×
Peer median: 5.8×

Protagonist Therapeutics' price to sales ratio is 31.8× as of Oct 23, 2026.

That is above its 8-year median of 15.4×, higher than on 74% of days in the last 8 years.

Over that time it ranged from 5.2× in May 2024 to 147× in Apr 2026.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	31.8×	24.0×	147×
2025	26.5×	5.3×	28.5×
2024	7.2×	5.2×	8.7×
2023	41.1×	16.3×	62.7×
2022	15.2×	8.5×	15.2×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	16.3×	7.6×	18.8×

Against its peers

Companies in Drug Manufacturers - General nearest Protagonist Therapeutics' size, closest first, today.

Company	Price to sales ratio
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
TGTXTG Therapeutics	10.4×
BMRNBiomarin Pharmaceutical	3.2×
ALKSAlkermes plc.	4.4×
AMRXAmneal Pharmaceuticals	2.1×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
JAZZJazz Pharmaceuticals	3.0×
INDVIndivior Pharmaceuticals	3.1×
ARQTArcutis Biotherapeutics	8.5×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Protagonist Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.